Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease

Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14.

Abstract

Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian carcinoma and resulting in approval of rucaparib for patients with both germline and somatic BRCA mutation. Data from the Phase III trial ARIEL3 led to approval in platinum-sensitive disease as maintenance. This article reviews the efficacy, safety, pharmacokinetics and pharmacodynamics of rucaparib as well as future and ongoing trials.

Keywords: BRCA mutated ovarian cancer; PARP; company tests; ovarian cancer; ovarian cancer maintenance treatment; platinum sensitive ovarian cancer; poly (ADP-ribose) polymerase inhibitors; rucaparib.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Drug Development
  • Epigenesis, Genetic
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Indoles / pharmacokinetics
  • Indoles / therapeutic use*
  • Loss of Heterozygosity
  • Mutation
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Poly(ADP-ribose) Polymerase Inhibitors / administration & dosage
  • Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacokinetics
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Recurrence
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Indoles
  • Poly(ADP-ribose) Polymerase Inhibitors
  • rucaparib